Alpa Laboratories share price
NSE: ALPABSE: 532878Pharmaceuticals & BiotechnologySmall Cap
Last close ₹49.29down ₹2.17 (4.22%)BSE ₹49.47
Share price at the NSE close on 23 Oct 2026. Previous close ₹51.46.
52-week range of traded prices to 23 Oct 2026
₹46.10Low, 30 Mar 2026₹93.85High, 31 Oct 2025
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹104 Cr2,659th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 23 Jul 2026
- 0.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 13 Aug 2026
- −1.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 23 Jul 2026
- 0.01
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 14,17675.0% delivered
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Jun 2026, against the quarter beforeFiled 13 Aug
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹24 Crdown 23.78%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹0.98 Crdown 29.10%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- 4.1%
Revenue by year
Peak revenue ₹112 Cr, year to Mar 2025
Net profit by year, a loss in red
| ₹ crore | Sep 2024Filed 15 Nov | Dec 2024Filed 13 Feb | Mar 2025Filed 16 Jun | Jun 2025Filed 13 Aug | Sep 2025Filed 15 Nov | Dec 2025Filed 11 Feb | Mar 2026Filed 23 Jul | Jun 2026Filed 13 Aug |
|---|---|---|---|---|---|---|---|---|
| Revenue | 24.9 | 26.2 | 39.9 | 19.1 | 26.3 | 29.0 | 31.4 | 23.9 |
| Net profit | 7.7 | 8.9 | −2.1 | 11.8 | 0.1 | 1.9 | 1.4 | 1.0 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | 30.8% | 34.0% | −5.3% | 61.6% | 0.4% | 6.6% | 4.4% | 4.1% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Drugs and Chemicals, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: a results filing in the last twelve months restated the quarters before it inside its year to date, so the four quarters as the company reported them do not add to a twelve-month profit; the ratio returns once the trailing year no longer holds a quarter from before the restatement. Not shown, EV/EBITDA: operating loss, last twelve months. Dividend yield is not shown: no dividend in the years on record.PE ratio and valuation history
Price to bookPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
At or below today's level on 22% of 1,949 trading days since Nov 2018.
LowestHighest
Its median1.0Industry median2.9
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −55.2% | −23.0% | −41.7% | 0.0% |
| 3 years | −4.8% | +5.9% | −10.1% | 0.0% |
| 5 years | +5.2% | +15.7% | −9.0% | 0.0% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth over 1, 3 and 5 years is on profit divided by shares in issue at both ends: the earnings per share stated for one end does not match that year's profit and share count.
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Alpa Laboratories in market cap. 2 companies in the table last traded before then: their rows are priced on their last trade.
Alpa Laboratories is not on the chart: it has no P/E or return on equity today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 BALAXI PHARMACEUTICALSBALAXI | 115 | 47.6 | 0.5 | 17.3 | −5.9% | −87.2% | 1.0% | 2.1% | 0.00% |
 Krebs Biochemicals and IndustriesKREBSBIO | 112 | – | – | – | −29.7% | – | – | −14.4% | 0.00% |
 Makers LaboratoriesMAKERSL | 110 | 32.3 | 1.5 | 6.1 | +17.6% | −61.6% | 4.8% | 11.1% | 0.00% |
 Tyche IndustriesTYCHE | 107 | 24.0 | 0.8 | – | −21.0% | −63.5% | 3.2% | −2.5% | 3.36% |
 Pharmaids PharmaceuticalsPHARMAID | 102 | – | 2.1 | – | +18.5% | – | −8.5% | −15.8% | 0.00% |
 Sotac PharmaceuticalsSOTAC | 102 | 17.6 | 1.7 | – | +0.1% | −28.2% | 10.3% | – | 0.22% |
 Veerhealth CareVEERHEALTH | 99 | 64.4 | 4.3 | 23.3 | +177.2% | +199.7% | 6.8% | 11.0% | 0.00% |
 Parmax PharmaPARMAX | 94 | – | – | – | −17.6% | – | – | −70.0% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
Sep 2026
7 Sep · Corporate action
Alpa Laboratories share price by year
Each calendar year to 2025.Alpa Laboratories share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 77.69 | −34.4% | 134.49 | 76.23 |
| 2024 | 118.46 | +14.7% | 139.20 | 74.60 |
| 2023 | 103.30 | +64.0% | 108.40 | 50.65 |
| 2022 | 63.00 | −20.7% | 106.00 | 49.30 |
| 2021 | 79.40 | +119.6% | 79.40 | 35.60 |
| 2020 | 36.15 | +113.9% | 47.60 | 11.80 |
| 2019 | 16.90 | −33.6% | 30.35 | 13.75 |
| 2018 | 25.45 | −40.0% | 52.35 | 23.55 |
| 2017 | 42.40 | +39.9% | 48.65 | 28.15 |
| 2016 | 30.30 | −60.2% | 77.90 | 27.25 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 23 Oct 2026 | 51.16 | 51.97 | 49.00 | 49.29 | 49.77 | 14,176 | 75.0% |
| 22 Oct 2026 | 52.00 | 52.90 | 49.50 | 51.46 | 51.68 | 7,598 | 71.6% |
| 21 Oct 2026 | 52.01 | 52.99 | 50.75 | 51.22 | 51.65 | 7,699 | 84.4% |
| 19 Oct 2026 | 51.01 | 54.28 | 51.01 | 52.25 | 52.71 | 5,277 | 74.0% |
| 16 Oct 2026 | 57.00 | 57.00 | 50.61 | 53.46 | 53.29 | 32,050 | 49.1% |
| 15 Oct 2026 | 59.00 | 59.00 | 55.60 | 55.96 | 56.55 | 9,093 | 75.8% |
| 14 Oct 2026 | 57.00 | 57.50 | 56.10 | 57.39 | 56.99 | 3,237 | 86.2% |
| 13 Oct 2026 | 55.80 | 58.59 | 55.00 | 57.87 | 56.88 | 13,946 | 55.7% |
| 12 Oct 2026 | 58.09 | 58.13 | 55.15 | 55.80 | 56.56 | 10,005 | 54.7% |
| 9 Oct 2026 | 56.00 | 57.00 | 55.15 | 56.99 | 56.15 | 10,206 | 48.5% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Legal name
- Alpa Laboratories Limited
- NSE symbol
- ALPA
- BSE code
- 532878
- ISIN
- INE385I01010
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Aug 2007
- Face value
- ₹10
- CIN
- L85195MP1988PLC004446
- Corporate identity number, the registrar of companies' code for it